Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ESPR vs TLPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ESPR Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

ESPR Overall Winner 6-Pillar Tally: ESPR 5 – 1 TLPH Matrix Metrics: ESPR 6 – 4 TLPH

As of Nov 16, 2026, Esperion Therapeutics, Inc. (ESPR) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ESPR carries a Unified Composite Score of 60.0/100 (BUY) at $3.18 (10.9x Forward P/E, -8.2% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin).

  • Technical & Structure Timing Caution: ESPR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.5); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ESPR vs TLPH
ESPR NASDAQ Head-to-Head Winner
Esperion Therapeutics, Inc.
Pharmaceutical Preparations
$3.18
-0.31% 1D
Market Cap $822.0M
TTM Revenue $418M
Forward P/E 10.9x
Beta / 30D Vol 1.86β · 6% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 64.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.5% over 20 days), RSI 64
RSI-14: 63.5 · SMA20: $3.16 · SMA50: $3.10
TLPH NASDAQ
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10

6-Pillar Scorecard Institutional Category Breakdown (ESPR 5 – 1 TLPH)

Columns: Metric · ESPR · TLPH
1. Valuation Multiples TLPH
Forward P/E 10.9x 1.0x
Trailing P/E 4.6x 1.0x
PEG Ratio N/M N/M
EV / Revenue 2.2x N/M
2. Growth & Scale ESPR
Revenue Growth (YoY) +23.2% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $418M $1,000
Market Cap $822.0M $53.7M
3. Profitability & Quality ESPR
Gross Margin 57.8% N/A
Operating Margin -8.2% -1474700.0%
Net Profit Margin -1.8% 0.0%
Return on Equity (ROE) -260.8% -143.4%
4. Balance Sheet & Cash Flow ESPR
Cash Generation (TTM) -$18M -$15M EBITDA
Cash Flow Margin -4.4% N/A
Net Cash / Leverage $96M Net Debt $0.28 Book/Sh · -143.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ESPR
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 12.5% (9th %ile) 118.4% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ESPR
OpEx & R&D Intensity 66.0% of Rev ($276M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ESPR (6) vs TLPH (4)
Institutional Metric ESPR TLPH Criterion Row Edge
Market Capitalization
Scale
$822.0M $53.7M Larger Scale ESPR
Trailing P/E Ratio
Valuation
4.6x 1.0x Lower Multiple TLPH
Forward P/E Ratio
Valuation
10.9x 1.0x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+23.2% +0.0% Higher Growth ESPR
Operating Margin (TTM)
Profitability
-8.2% -1474700.0% Higher Margin ESPR
Net Profit Margin
Profitability
-1.8% 0.0% Higher Margin TLPH
Return on Equity (ROE)
Capital Efficiency
-260.8% -143.4% Higher ROE TLPH
52-Week Range Position
Momentum
68% ($1–$4) 20% ($1–$2) Stronger Trend ESPR
Beta / 30D Volatility
Risk Regime
1.86β · 6% Vol 1.11β · 58% Vol Lower Realized Risk ESPR
Unified Institutional Score
Composite Signal
60.0 / 100 (BUY) 37.1 / 100 (SELL) Higher Composite ESPR
Trailing 12M Revenue (USD)
Operating Scale
$418M $1,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
57.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$18M ($96M Net Debt) -$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TLPH +77.74 pp
ESPR: +1.27% · TLPH: +79.01%
3M Horizon TLPH +33.89 pp
ESPR: +45.87% · TLPH: +79.76%
6M Horizon TLPH +33.06 pp
ESPR: -17.19% · TLPH: +15.87%
1Y Horizon TLPH +31.62 pp
ESPR: +7.43% · TLPH: +39.05%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ESPR vs TLPH. Trailing 12-month operating profitability (ESPR -8.2% vs TLPH -1474700.0%) and valuation multiples (ESPR 10.9x vs TLPH 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.

ESPR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$418M
Gross Margin57.8%
Op. Margin-8.2%
ROE / Fwd P/E-260.8% · 10.9x
TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ESPR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 12.5%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ESPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ESPR Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $822.0M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment 66.0% of Rev ($276M)
90D Engineering Disclosures 0 Published
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ESPR vs TLPH Key Questions & Quantitative Answers

As of Nov 16, 2026, Esperion Therapeutics, Inc. (ESPR) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ESPR carries a Unified Composite Score of 60.0/100 (BUY) at $3.18 (10.9x Forward P/E, -8.2% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin). Technical & Structure Timing Caution: ESPR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.5); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ESPR leads the Growth & Scale pillar: ESPR posts +23.2% YoY revenue growth and +0.0% YoY earnings growth on $418M TTM revenue (57.8% gross margin, -8.2% operating margin), compared with TLPH at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin). On trailing 12-month operating scale, ESPR generates $418M in USD-normalized revenue versus $1,000 for TLPH. In operating R&D and SG&A reinvestment, ESPR deploys 66.0% of Rev ($276M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TLPH.

TLPH screens cheaper on headline valuation multiples. ESPR trades at 10.9x Forward P/E, 4.6x Trailing P/E, N/M PEG, and 2.2x EV/Revenue (-4.4% FCF margin), whereas TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ESPR (-260.8% ROE) versus TLPH (-143.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ESPR carries 12.5% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.86β · 6% Vol realized risk). By comparison, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.